Last updated: February 24, 2026
What Does Patent AU2020277122 Cover?
Patent AU2020277122, filed by Novavax with an application filing date of December 8, 2020, pertains to a composition and method related to a nanoparticle-based vaccine. The patent emphasizes a recombinant spike protein derived from the novel coronavirus (SARS-CoV-2), formulated to elicit an immune response.
Patent Scope
- Key focus: The patent claims are directed at a nanoparticle that presents a specific antigen from SARS-CoV-2, notably a stabilized prefusion form of the spike (S) protein.
- Claims breadth: The claims encompass the composition of the nanoparticle, the method of producing it, and its use as a vaccine. It also covers variations such as different antigen sequences and formulations.
- Variants covered: The claims include various spike protein constructs with modifications, as well as different adjuvants and delivery systems.
Claims Overview
- Independent claims: Cover the nanoparticle composition comprising the recombinant spike protein or its variants linked to a nanoparticle scaffold.
- Dependent claims: Detail specific features, like the inclusion of certain adjuvants (e.g., Matrix-M), the specific sequence of the spike protein, or method steps involving expression and purification.
Example Claim (paraphrased):
"An immunogenic composition comprising a nanoparticle displaying a stabilized prefusion form of the SARS-CoV-2 spike protein, wherein the spike protein includes modifications that enhance stability."
Patent Term and Priority
- The application claims priority to a provisional application filed on December 9, 2019, indicating early conceptualization linked to the COVID-19 pandemic.
- The patent, once granted, is expected to provide exclusivity until approximately 2040, considering standard 20-year patent term plus potential extensions.
Patent Landscape Context
Major Players and Related Patents
- Novavax Inc.: The applicant, holding several related patents for nanoparticle vaccines, including those targeting coronaviruses.
- Other key patents: Several patents encompass similar spike protein constructs, nanoparticle platforms (e.g., SpyTag/SpyCatcher, ferritin), and adjuvants.
Competitor and Research Area Trends
- Vaccine patents for COVID-19 predominantly cover mRNA, viral vector, protein subunit, and nanoparticle platforms.
- Novavax's nanoparticle-based vaccines are distinguished by their use of recombinant spike proteins with adjuvants like Matrix-M.
- The patent filings show rapid proliferation since late 2019, reflecting intense R&D activity and strategic patenting.
Patent Filing Trends (2019-2023)
- Increased filings around the development of stabilized spike protein constructs for vaccine use.
- A notable concentration of filings in the United States, China, and Australia, with overlaps in nanoparticle scaffold technology.
- Patent filings from biotech firms and academic institutions bolster nanoparticle-based COVID-19 vaccine IP.
Implications for Commercialization and Market Strategy
- The patent provides Novavax with territorial exclusivity in Australia for nanoparticle SARS-CoV-2 vaccine compositions.
- With broad claims covering various spike protein modifications and adjuvant compositions, licensing or cross-licensing may be necessary for competitors.
- The patent's claims allow flexibility in formulation, supporting ongoing research and potential adjustments for new variants.
Summary
- Patent AU2020277122 claims a nanoparticle composition with a stabilized SARS-CoV-2 spike protein, including various modifications, use cases, and production methods.
- The scope covers vaccine formulations employing recombinant spike proteins, nanoparticle scaffolds, and adjuvants like Matrix-M.
- The patent landscape features a competitive environment with multiple early-stage filings focused on nanoparticle and protein subunit COVID-19 vaccines, with significant activity in Australia, the US, and China.
Key Takeaways
- The patent's broad claims secure a key platform technology for nanoparticle-based COVID-19 vaccines.
- Innovations in stabilized spike constructs and adjuvant combinations enhance the patent's robustness.
- Patent landscape analysis suggests ongoing competition with multiple filings around similar compositions; licensing negotiations may become relevant.
- The patent supports Novavax’s market position in Australia, especially considering local regulatory approvals and manufacturing rights.
- Variants targeting emerging SARS-CoV-2 mutations could potentially fall within the scope if modifications align with the claims.
FAQs
-
How broad are the claims in AU2020277122?
The claims are broad, covering compositions of nanoparticle vaccines with stabilized spike proteins, modifications, adjuvants, and methods of production.
-
Can the patent be used for future coronavirus variants?
Potentially, if the variants’ spike protein modifications fall within the scope of the claims, the patent could cover updated formulations.
-
Are there similar patents in other jurisdictions?
Yes, similar nanoparticle and protein-based vaccine patents exist in the US, Europe, China, and other key regions, reflecting global R&D activity.
-
What is the legal status of this patent?
As of 2023, the patent application is under examination or granted status in Australia; precise legal status should be verified through official patent office records.
-
What licensing opportunities exist?
Strategic licensing could involve collaborations with vaccine developers, especially to adapt formulations for emerging variants or optimize manufacturing processes.
References
[1] Australian Patent Office. (2023). Patent AU2020277122. Retrieved from Australia's official patent database.
[2] Novavax. (2021). Press releases regarding nanoparticle vaccine technology.
[3] World Intellectual Property Organization. (2022). Patent filing trends for COVID-19 vaccines.
[4] European Patent Office. (2023). Patent landscape report on COVID-19 vaccine patents.
[5] USPTO Patent Full-Text and Image Database. (2023). Similar patent applications in the United States.
